PVLA
Palvella Therapeutics, Inc.
Biotechnology
Market Cap$1.44B
5Y Perf.+910.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
PVLA vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.88B
5Y Perf.+16.8%
PVLA vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PVLA | IMVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.44B | $5.88B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-49M | $-464M |
| Total Debt | $633K | $98K |
| Cash & Equiv. | $58M | $714M |
PVLA vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PVLA
IMVT
| Stock | Dec 24 | May 26 | Return |
|---|---|---|---|
| Palvella Therapeuti… (PVLA) | 100 | 1010.8 | +910.8% |
| Immunovant, Inc. (IMVT) | 100 | 116.8 | +16.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PVLA vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PVLA leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Immunovant, Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
PVLA
Palvella Therapeutics, Inc.
The Growth Play
PVLA carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- EPS growth 52.6%
- 6.1% 10Y total return vs IMVT's 190.9%
- 79.5% revenue growth vs IMVT's -21.3%
Best for: growth exposure and long-term compounding
IMVT
Immunovant, Inc.
The Income Pick
IMVT is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.36
- Lower volatility, beta 1.36, Low D/E 0.0%, current ratio 11.16x
- Beta 1.36, current ratio 11.16x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PVLA | 79.5% revenue growth vs IMVT's -21.3% |
| Quality / Margins | IMVT | 3.2% margin vs PVLA's -5.4% |
| Stability / Safety | IMVT | Beta 1.36 vs PVLA's 1.39, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | PVLA | +426.4% vs IMVT's +102.4% |
| Efficiency (ROA) | PVLA | -42.5% ROA vs IMVT's -44.1% |
PVLA vs IMVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPVLALAGGINGIMVT
IMVTImmunovant, Inc.
2leads
PVLAPalvella Therapeutics…
2leads
6 Total Categories
CATEGORYLEADERvs IMVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PVLA1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IMVT4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
PVLA6/6
Risk & VolatilityBeta, volatility, and downside exposure
IMVT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PVLA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
PVLA and IMVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | PVLAPalvella Therapeu… | IMVTImmunovant, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$19M | -$487M |
| Net IncomeAfter-tax profit | -$49M | -$464M |
| Free Cash FlowCash after capex | -$18M | -$423M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +67.4% | +19.7% |
PVLA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — PVLA and IMVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | PVLAPalvella Therapeu… | IMVTImmunovant, Inc. |
|---|---|---|
| Market CapShares × price | $1.4B | $5.9B |
| Enterprise ValueMkt cap + debt − cash | $1.4B | $5.2B |
| Trailing P/EPrice ÷ TTM EPS | -32.69x | -10.60x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 48.77x | 6.20x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — PVLA and IMVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
IMVT leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
IMVT delivers a -47.1% return on equity — every $100 of shareholder capital generates $-47 in annual profit, vs $-57 for PVLA. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to PVLA's 0.02x.
| Metric | PVLAPalvella Therapeu… | IMVTImmunovant, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -56.9% | -47.1% |
| ROA (TTM)Return on assets | -42.5% | -44.1% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -62.1% | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 |
| Debt / EquityFinancial leverage | 0.02x | 0.00x |
| Net DebtTotal debt minus cash | -$57M | -$714M |
| Cash & Equiv.Liquid assets | $58M | $714M |
| Total DebtShort + long-term debt | $633,000 | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | -11.28x | — |
IMVT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
PVLA leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PVLA five years ago would be worth $71,347 today (with dividends reinvested), compared to $18,445 for IMVT. Over the past 12 months, PVLA leads with a +426.4% total return vs IMVT's +102.4%. The 3-year compound annual growth rate (CAGR) favors PVLA at 92.5% vs IMVT's 14.4% — a key indicator of consistent wealth creation.
| Metric | PVLAPalvella Therapeu… | IMVTImmunovant, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +21.0% | +11.7% |
| 1-Year ReturnPast 12 months | +426.4% | +102.4% |
| 3-Year ReturnCumulative with dividends | +613.5% | +49.8% |
| 5-Year ReturnCumulative with dividends | +613.5% | +84.4% |
| 10-Year ReturnCumulative with dividends | +613.5% | +190.9% |
| CAGR (3Y)Annualised 3-year return | +92.5% | +14.4% |
PVLA leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
IMVT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
IMVT is the less volatile stock with a 1.36 beta — it tends to amplify market swings less than PVLA's 1.39 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 96.2% from its 52-week high vs PVLA's 80.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PVLAPalvella Therapeu… | IMVTImmunovant, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.39x | 1.36x |
| 52-Week HighHighest price in past year | $151.18 | $30.09 |
| 52-Week LowLowest price in past year | $20.20 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +80.2% | +96.2% |
| RSI (14)Momentum oscillator 0–100 | 38.7 | 50.6 |
| Avg Volume (50D)Average daily shares traded | 257K | 1.4M |
IMVT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates PVLA as "Buy" and IMVT as "Buy". Consensus price targets imply 68.1% upside for PVLA (target: $204) vs 57.2% for IMVT (target: $46).
| Metric | PVLAPalvella Therapeu… | IMVTImmunovant, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $203.92 | $45.50 |
| # AnalystsCovering analysts | 10 | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PVLA leads in 2 of 6 categories (Income & Cash Flow, Total Returns). IMVT leads in 2 (Profitability & Efficiency, Risk & Volatility). 1 tied.
Best OverallPalvella Therapeutics, Inc. (PVLA)Leads 2 of 6 categories
Loading custom metrics...
PVLA vs IMVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PVLA or IMVT a better buy right now?
Analysts rate Palvella Therapeutics, Inc.
(PVLA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PVLA or IMVT?
Over the past 5 years, Palvella Therapeutics, Inc.
(PVLA) delivered a total return of +613. 5%, compared to +84. 4% for Immunovant, Inc. (IMVT). Over 10 years, the gap is even starker: PVLA returned +613. 5% versus IMVT's +190. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PVLA or IMVT?
By beta (market sensitivity over 5 years), Immunovant, Inc.
(IMVT) is the lower-risk stock at 1. 36β versus Palvella Therapeutics, Inc. 's 1. 39β — meaning PVLA is approximately 2% more volatile than IMVT relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 2% for Palvella Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — PVLA or IMVT?
On earnings-per-share growth, the picture is similar: Palvella Therapeutics, Inc.
grew EPS 52. 6% year-over-year, compared to -45. 2% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PVLA or IMVT?
Palvella Therapeutics, Inc.
(PVLA) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PVLA leads at 0. 0% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — PVLA leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PVLA or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PVLA or IMVT better for a retirement portfolio?
For long-horizon retirement investors, Palvella Therapeutics, Inc.
(PVLA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+613. 5% 10Y return). Both have compounded well over 10 years (PVLA: +613. 5%, IMVT: +190. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PVLA and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.